» Articles » PMID: 37596540

Allicin Protects Against LPS-induced Cardiomyocyte Injury by Activating Nrf2-HO-1 and Inhibiting NLRP3 Pathways

Overview
Publisher Biomed Central
Date 2023 Aug 18
PMID 37596540
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Allicin is a bioactive compound with potent antioxidative activity and plays a protective effect in myocardial damage and fibrosis. The role and mechanism of Allicin in septic cardiomyopathy are unclear. In this study, we investigated the effects and underlying mechanisms of Allicin on lipopolysaccharide (LPS) induced injury in H9c2 cardiomyocytes.

Methods: H9c2 cardiomyocyte cells were pretreated with Allicin (0, 25, 50, and 100 µM) for 2 h, followed by incubation with LPS (10 µg/mL) for 24 h at 37 °C. Cell viability (cell counting kit-8 [CCK-8]), apoptosis (TUNEL staining), oxidative stress (malondialdehyde [MDA] and superoxide dismutase [SOD]), and cytokines release (Interleukin beta [IL-β], Interleukin 6 [IL-6], and tumor necrosis factor-alpha [TNF-α]) were determined. The mRNA and protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), and NLR family pyrin domain containing 3 (NLRP3) signaling pathway molecules were quantified by real-time quantitative PCR (RT-qPCR) and western blot, respectively.

Results: Allicin had no effect on H9c2 cell viability but attenuated LPS-induced injury, with increased cell viability, reduction in inflammatory cytokines release, apoptosis, reduced MDA, and increased SOD (P < 0.05). Additionally, Allicin increased Nrf2 and cellular HO-1 expressions in LPS-treated H9c2 cells. Moreover, Allicin modulated the NLRP3 inflammasome, increased the cleaved caspase-1 (p10) protein, and attenuated the LPS-induced increase in NLRP3, pro-IL-1β, and IL-1β proteins. Silencing of Nrf2 by siRNA (siNrf2) significantly attenuated Allicin-induced increase in cell viability and HO-1 and decrease in NLRP3 protein in LPS-stimulated H9c2 cells.

Conclusions: Allicin protects cardiomyocytes against LPS‑induced injury through activation of Nrf2/HO-1 and inhibition of NLRP3 signaling pathways.

Citing Articles

Therapeutic potentials of allicin in cardiovascular disease: advances and future directions.

Gao Y, Wang B, Qin G, Liang S, Yin J, Jiang H Chin Med. 2024; 19(1):93.

PMID: 38956680 PMC: 11218272. DOI: 10.1186/s13020-024-00936-8.


Regulation of ROS/inflammasome Axis is Essential for Cardiac Regeneration in Aging Rats Receiving Transplantation of Mesenchymal Stem Cells.

Hu W, Chen J, Liao W, Chang C, Chen T Curr Stem Cell Res Ther. 2023; 19(10):1393-1401.

PMID: 38031779 DOI: 10.2174/011574888X276612231121065203.

References
1.
Vincent J . The Clinical Challenge of Sepsis Identification and Monitoring. PLoS Med. 2016; 13(5):e1002022. PMC: 4871479. DOI: 10.1371/journal.pmed.1002022. View

2.
Tsiotou A, Sakorafas G, Anagnostopoulos G, Bramis J . Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit. 2005; 11(3):RA76-85. View

3.
Rudd K, Johnson S, Agesa K, Shackelford K, Tsoi D, Kievlan D . Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020; 395(10219):200-211. PMC: 6970225. DOI: 10.1016/S0140-6736(19)32989-7. View

4.
Walley K . Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 2018; 24(4):292-299. DOI: 10.1097/MCC.0000000000000507. View

5.
Kong W, Kang K, Gao Y, Liu H, Meng X, Yang S . Dexmedetomidine alleviates LPS-induced septic cardiomyopathy via the cholinergic anti-inflammatory pathway in mice. Am J Transl Res. 2017; 9(11):5040-5047. PMC: 5714788. View